Search for:

In brief

With a communication dated 11 January 2021, the European Commission has recognized the possibility for Notified Bodies to perform remote audits on medical devices aimed at verifying compliance with applicable safety and effectiveness and obtaining the CE marking.


  • This decision addresses the requests from Member States, Notified Bodies and medical device companies who informed the Commission that travel and quarantine restrictions imposed in response to the COVID-19 pandemic have significantly affected Notified Bodies’ ability to conduct on-site audits on the premises, which could raise the risk of shortages of vital devices.
  • In this respect, the Commission nevertheless pointed out that the failure of Notified Bodies to carry out on-site audits should be limited in time, identified and justified on a case-by-case basis and not go beyond what is required to ensure continuous availability of safe and performant devices, when concrete obstacles to complete conformity assessments on-site have been created by COVID-19 circumstances.

Lastly, the Commission recalled the obligation of Member States authorities to monitor Notified Bodies established on their territory to ensure that they comply with the requirements laid down in the applicable legislation and stressed the fact that, in case of non-compliance, national authorities shall suspend, restrict, or fully or partially withdraw the designation, depending on the seriousness of the failure to fulfill those obligations.

Author

Roberto Cursano has been a lawyer in Baker McKenzie since September 2007. He focuses on healthcare law and compliance, and assists in tender procedures, the negotiation of public contracts and litigation before administrative courts. Mr. Cursano is a former administrative officer in the Italian Ministry of Health and helps clients work closely with the Italian Public Administration. He is admitted to the bar before the Italian Supreme Court and the Council of State. As well as training and tutoring in the master’s degree program on clinical trials of pharmaceutical products at the University of Rome Sapienza, Mr. Cursano regularly publishes articles and scientific contributions. He also frequently hosts and participates in seminars and presentations on pharmaceutical and administrative law matters.

Author

Riccardo Ovidi is an Associate in Baker McKenzie Rome office.